Overview of the Investigation
Glancy Prongay & Murray LLP, a prominent law firm specializing in shareholder rights, has initiated an investigation into potential securities violations by MoonLake Immunotherapeutics (NASDAQ: MLTX). This inquiry comes in light of recent developments that have raised concerns among investors regarding the company’s transparency and the efficacy of its leading drug candidate, sonelokimab (referred to as SLK).
According to reports, on September 28, 2025, MoonLake disclosed that the results from the Phase 3 trials of SLK were underwhelming, as the drug did not outperform its competitor, Union Chimique Belge‘s bimekizumab-bkz. The company had previously touted the innovative nanobody design of SLK, suggesting it offered distinct advantages over traditional monoclonal antibodies. However, it appears that the company may have failed to adequately disclose that SLK targeted similar molecules without demonstrating any proven superiority.
Impact on Investors
The ramifications of this announcement were swift and severe, resulting in a drastic drop in MoonLake’s stock price. Following the disclosure, shares plummeted by approximately 89.9%, closing at $6.24 each on September 29, a decline of $55.74 per share. This sharp decline has left many investors facing significant financial losses and has prompted calls for accountability regarding the company’s practices and disclosures.
In response to these events, Glancy Prongay & Murray LLP has reached out to affected investors, encouraging them to consider pursuing claims to recover their losses. The firm is inviting individuals who have suffered financial harm due to their investments in MoonLake to inquire about their rights and potential legal actions.
Whistleblower Opportunities
Additionally, the law firm is highlighting the possibility for whistleblowers with insider information about MoonLake to contribute to the investigation. Under the SEC Whistleblower Program, individuals providing original information may be eligible for rewards of up to 30% of any successful recovery made by the SEC.
For those interested in learning more about this investigation or seeking legal counsel, Charles Linehan, an attorney at Glancy Prongay & Murray LLP, is available for inquiries. The firm operates from its office in Los Angeles, California, and offers various channels for communication, including email and telephone.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP is recognized as a leading law firm in the field of securities litigation and has a strong track record of representing investors in complex legal matters. With a solid reputation for handling cases involving corporate misconduct across various industries, the firm has secured billions in settlements for its clients and has been acknowledged in numerous financial publications for its achievements.
As MoonLake Immunotherapeutics navigates this challenging period, the outcome of the ongoing investigation will be closely monitored by both investors and industry analysts alike, as it may set a precedent regarding corporate accountability and transparency in the biopharmaceutical sector.
Related
